Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The establishment of kidney cancer organoid line in drug testing.

Cancer medicine - 1 Jun 2024

Tse Ryan Tsz-Hei, Wong Christine Yim-Ping, Ding Xiaofan, Cheng Carol Ka-Lo, Chow Chit, Chan Ronald Cheong-Kin, Ng Joshua Hoi-Yan, Tang Victor Wai-Lun, Chiu Peter Ka-Fung, Teoh Jeremy Yuen-Chun, Wong Nathalie, To Ka-Fai, Ng Chi-Fai

Abstract excerpt

INTRODUCTION: Kidney cancer is a common urological malignancy worldwide with an increasing incidence in recent years. Among all subtypes, renal cell carcinoma (RCC) represents the most predominant malignancy in kidney. Clinicians faced a major challenge to select the most effective and suitable treatment regime for patients from a wide range of modalities, despite improved understanding and diagnosis of RCC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Screening Assays, Antitumor

Share to Kidney Neoplasms

Share to Organoids

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38923304
DOI: 10.1002/cam4.7432
PMCID: PMC11200131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The establishment of kidney cancer organoid line in drug testing.PMID 38923304Read ↗

Patient-derived renal cell carcinoma organoids for precision medicineSemantic proximity Read ↗

Choosing the right cell line for renal cell cancer researchSemantic proximity Read ↗

Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.Semantic proximity Read ↗

Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug ScreeningSemantic proximity Read ↗

Studying Kidney Diseases Using Organoid ModelsSemantic proximity Read ↗

Modeling methods of different tumor organoids and their application in tumor drug resistance researchSemantic proximity Read ↗

Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid modelsSemantic proximity Read ↗

An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneitySemantic proximity Read ↗

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.Semantic proximity Read ↗

Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agentsSemantic proximity Read ↗

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patientsSemantic proximity Read ↗

Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.